when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

PD-L1 · news · pharmadog

← back to PD-L1

News · PD-L1

41 stories

3dBMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsbiospace

6dSummit snags $2B investment from AstraZeneca, clearing financial overhangbiospace

7dMerck, Daiichi Sankyo retract accelerated approval request for lung cancer ADCbiospace

21dSummit, Akeso look to shed PD-1/VEGF drug doubts with latest study resultsbiopharma dive

21dSummit, BioNTech, more headline WCLC with next-gen lung cancer drugsbiospace

25dFDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancerfiercebiotech

27dSolstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2fiercebiotech

27dInhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancerbiospace

28dInhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durabilityfiercebiotech

Sep 3, 26Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—againbiospace

Sep 2, 26Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial failsbiospace

Aug 26, 26Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debatefiercebiotech

Aug 17, 26AstraZeneca scraps Phase 3 trial of new bispecific in lung cancerbiopharma dive

Aug 17, 26STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and morestat

Aug 17, 26AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowbiospace

Aug 17, 26AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowbiospace

Aug 17, 26AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytrudafiercebiotech

Jul 29, 26Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combinationfiercebiotech

Jul 27, 26AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failurebiospace

Jul 27, 26Summit, Merck must navigate new regulatory terrain in China-first cancer landscapebiospace

Jul 15, 26Merck ADC, in China study, shows potential to replace chemo in lung cancerbiopharma dive

Jul 15, 26Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytrudabiospace

Jun 9, 26Gilead and Merck’s latest trial success and flopstat

Jun 5, 26Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?biopharma dive

May 29, 26At ASCO, Merck makes case for a ‘cornerstone’ cancer drugbiopharma dive

May 16, 26Genomic Disease Burden Markers, PD-L1 Expression Predictive of pOR With Neoadjuvant Gem-iDRS ± Cetrelimab in MIBConclive

May 14, 26HERIZON-GEA-01 Efficacy Results and Interpretation of Duration of Responseonclive

May 13, 26Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumorsonclive

May 12, 26GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026onclive

May 11, 26INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCConclive

← prevpage 1 of 2next →